Back to Search
Start Over
Fluoxetine in tricyclic refractory major depressive disorder
- Source :
- Journal of Affective Disorders. 20:193-200
- Publication Year :
- 1990
- Publisher :
- Elsevier BV, 1990.
-
Abstract
- Data regarding open-label treatment with fluoxetine following failure to respond to tricyclic antidepressants (TCAs) or intolerance of TCA side effects, suggest a response rate between 51.4% and 62.1%, depending on the definition of TCA refractoriness employed. Double-blind study of this issue would extend these findings. Fluoxetine is well tolerated in patients unable to tolerate TCAs. Within this population, more than 80% of patients unable to tolerate TCAs found fluoxetine acceptable. Fluoxetine, as an alternative to polypharmaceutical augmentation, may represent a logical choice as the next step in therapy for a patient who has initially been treated with a TCA and has proven refractory or intolerant.
- Subjects :
- Adult
Male
medicine.medical_specialty
Refractory period
medicine.medical_treatment
Population
Antidepressive Agents, Tricyclic
Pharmacology
Drug Administration Schedule
Double-Blind Method
Refractory
Recurrence
Fluoxetine
medicine
Humans
education
Psychiatry
Depression (differential diagnoses)
Psychiatric Status Rating Scales
chemistry.chemical_classification
Depressive Disorder
education.field_of_study
Chemotherapy
Dose-Response Relationship, Drug
Middle Aged
medicine.disease
humanities
Psychiatry and Mental health
Clinical Psychology
chemistry
Major depressive disorder
Female
Psychology
Tricyclic
medicine.drug
Subjects
Details
- ISSN :
- 01650327
- Volume :
- 20
- Database :
- OpenAIRE
- Journal :
- Journal of Affective Disorders
- Accession number :
- edsair.doi.dedup.....8e57fb98fe8f686609a592e67c989eea